Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over: technology appraisal guidance

Pickett, Karen, Ribeiro, Ines, Picot, Jo, Cooper, Keith and Scott, David Alexander (2024) Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over: technology appraisal guidance National Institute for Health and Care Excellence 174pp.

Record type: Monograph (Project Report)

Abstract

This report is a critique of the company’s submission (CS) to NICE from Almirall on the clinical effectiveness and cost effectiveness of lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over. It identifies the strengths and weaknesses of the CS.

Text

Lebrikizumab ID4025 EAG report - Version of Record

Available under License Other.

Download (1MB)

More information

Published date: 10 July 2024

Related URLs:

https://www.nice.org.uk/guidance/ta986

Identifiers

Local EPrints ID: 495566

URI: http://eprints.soton.ac.uk/id/eprint/495566

PURE UUID: 1f65b599-761b-4a45-9704-f56f1e549e47

ORCID for Karen Pickett:

orcid.org/0000-0002-8631-6465

ORCID for Ines Ribeiro:

orcid.org/0000-0001-8464-4513

ORCID for Jo Picot:

orcid.org/0000-0001-5987-996X

ORCID for Keith Cooper:

orcid.org/0000-0002-0318-7670

ORCID for David Alexander Scott:

orcid.org/0000-0001-6475-8046

Catalogue record

Date deposited: 18 Nov 2024 17:41

Last modified: 19 Nov 2024 02:58

Export record

Share this record

Share this on Facebook Share this on Twitter Share this on Weibo

Contributors

Author: Karen Pickett

Author: Ines Ribeiro

Author: Jo Picot

Author: Keith Cooper

Author: David Alexander Scott

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Library staff additional information